Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One RNAi-Related Patent, Eight Patent Applications

Premium

Title: Methods and Means for Producing [an] Efficient Silencing Construct Using Recombinational Cloning

Number: 6,933,146

Filed: Jan. 25, 2002

Lead Inventor: Christopher Helliwell, Commonwealth Scientific and Industrial Research Organization

According to the patent's abstract, the invention comprises "methods and vectors and kits … for producing chimeric nucleic acid constructs capable of producing dsRNA for silencing target nucleic acid sequences of interest using recombinational cloning."


Title: siRNA Expression System and Method for Producing [a] Functional Gene Knockdown Cell Using the System

Number: 20050197315

Filed: May 13, 2005

Lead Inventor: Kazunari Taira, Toudai

The patent application, its abstract states, covers an "in vivo siRNA expression system … that intracellularly expresses small interfering RNAs and comprises antisense and sense code DNAs coding for antisense and sense RNAs targeting any region of a target gene mRNA and one or more promoters that function to express the antisense and sense RNAs from the antisense and sense code DNAS, respectively."


Title: Multiple Promoter Expression Cassettes for Simultaneous Delivery of siRNA Agents

Number: 20050197313

Filed: March 4, 2005

Lead Inventor: Petrus Roelvink, Benitec

"The … invention provides multiple-promoter expression cassettes for simultaneous delivery of RNAi, preferably to mammalian cells in vivo," according to the patent application's abstract.


Title: Transcription Factor RNA Interference Reagents and Methods of Use Thereof

Number: 20050197312

Filed: March 2, 2005

Lead Inventor: Kevin Fitzgerald, Bristol-Myers Squibb

"The … invention concerns methods and reagents useful in modulating transcription factor gene expression in a variety of applications, including methods of use in therapeutic, diagnostic, target validation, and genomic discovery applications," the patent application's abstract states. "Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, and double-stranded RNA molecules capable of mediating RNA interference against E2F1, NFkB, CREB-1, and/or CDC2A gene expression, useful in the treatment of cell cycle disorders, inflammatory conditions, reproductive disorders, cancers and any other condition that responds to modulation of E2F1, NFkB, CREB-1, and/or CDC2A expression and/or activity."


Title: Oligoribonucleotides and Methods of Use Thereof for [the] Treatment of Cystic Fibrotic Conditions and Other Diseases

Number: 20050197310

Filed: Jan. 27, 2005

Lead Inventor: Orna Mor, Quark Biotech

According to the patent application's abstract, the invention "relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier," the abstract notes.

"The … invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular, scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient," the abstract states. "The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide."


Title: DNA Cassette for Cellular Expression of Small RNA

Number: 20050196862

Filed: Aug. 29, 2003

Lead Inventor: Christine Wooddell, Mirus Bio

"We describe expression cassettes and processes for preparing expression cassettes that can be delivered to animal cells in vivo or in vitro," the patent application's abstract states. "Delivery of the cassettes results in expression of small RNA transcripts such as siRNA in the cell. The cassettes can be used to inhibit gene expression in the cell and to screen siRNA and other RNA sequences for functional efficacy."


Title: RNA Interference-Mediated Inhibition of STAT3 Gene Expression Using Short Interfering Nucleic Acid

Number: 20050196781

Filed: Dec. 15, 2004

Lead Inventor: Howard Robin, Sirna Therapeutics

"This invention relates to compounds, compositions, and methods useful for modulating STAT3 gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of STAT3 gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of STAT3 genes.

"Such small nucleic acid molecules are useful, for example, for treating, preventing, inhibiting, or reducing cancer, proliferative, and/or inflammatory diseases, disorders, or conditions in a subject or organism, such as psoriasis, eczema, dermatitis, Crohn's disease, and inflammatory bowel disease, and for any other disease, trait, or condition that is related to or will respond to the levels of STAT3 in a cell or tissue, alone or in combination with other treatments or therapies," the abstract adds.


Title: RNA Interference-Mediated Inhibition of GRB2-Associated Binding Protein (GAB2) Gene Expression Using Short Interfering Nucleic Acid

Number: 20050196767

Filed: Aug. 20, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

According to the patent application's abstract, "this invention relates to compounds, compositions, and methods useful for modulating GRB2 associated binding protein gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of GRB2 associated binding protein gene expression and/or activity by RNA interference using small nucleic acid molecules," the abstract states.

"In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of GAB2 genes," the abstract adds. "The small nucleic acid molecules are useful in the treatment of cancer, malignant blood disease [such as] leukemia, inflammatory diseases or conditions, allergic diseases or conditions, or proliferative diseases or conditions."


Title: RNA Interference-Mediated Inhibition of Checkpoint Kinase-1 (CHK-1) Gene Expression Using Short Interfering Nucleic Acid

Number: 20050196765

Filed: July 23, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

"This invention relates to compounds, compositions, and methods useful for modulating checkpoint kinase (e.g., checkpoint kinase-1 or CHK-1) gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of checkpoint kinase gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of checkpoint kinase genes."

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.